Back to search
FDAFDA · Food and drugs·Recall number D-1435-2014

Diltiazem HCl Extended-release Capsules, USP, 120 mg, packaged in 80 Capsules (8 x 10) blister cards per carton, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 51079-947-08.

Published July 23, 2014 · Recall initiated: July 3, 2014

Summary

FDA records drug Class III recall D-1435-2014, published July 23, 2014 and initiated July 3, 2014. Recalling firm: Mylan Institutional, Inc. (d.b.a. UDL Laboratories); Status: Terminated; Reported quantity: 1,184 cartons; Lot: Lot #: 3045659, 3048256, Exp 07/14. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: High out-of-specification results for a related compound obtained during routine stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
Distributor
Nationwide, Puerto Rico, and Guam.
Lot
Lot #: 3045659, 3048256, Exp 07/14
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Diltiazem HCl Extended-release Capsules, USP, 120 mg, packaged in 80 Capsules (8 x 10) blister cards per carton, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 51079-947-08. recalled?

Yes. FDA published recall D-1435-2014 on July 23, 2014. Reported hazard: Failed Impurities/Degradation Specifications: High out-of-specification results for a related compound obtained during routine stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter